Croome Kristopher P
Department of Transplant, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
J Clin Med. 2023 Jan 23;12(3):909. doi: 10.3390/jcm12030909.
While adoption of machine perfusion technologies into clinical practice in the United States has been much slower than in Europe, recent changes in the transplant landscape as well as device availability following FDA approval have paved the way for rapid growth. Machine perfusion may provide one mechanism to maximize the utilization of potential donor liver grafts. Indeed, multiple studies have shown increased organ utilization with the implementation of technologies such as ex-situ normothermic machine perfusion (NMP), ex-situ hypothermic machine perfusion (HMP) and in-situ normothermic regional perfusion (NRP). The current review describes the history and development of machine perfusion utilization in the Unites States along with future directions. It also describes the differences in landscape between Europe and the United States and how this has shaped clinical application of these technologies.
虽然美国将机器灌注技术应用于临床实践的速度比欧洲慢得多，但移植领域最近的变化以及美国食品药品监督管理局（FDA）批准后设备的可获得性为其快速发展铺平了道路。机器灌注可能提供一种机制，以最大限度地利用潜在的供体肝脏移植物。事实上，多项研究表明，采用诸如体外常温机器灌注（NMP）、体外低温机器灌注（HMP）和原位常温区域灌注（NRP）等技术可提高器官利用率。本综述描述了美国机器灌注利用的历史和发展以及未来方向。它还描述了欧洲和美国在情况上的差异以及这如何影响了这些技术的临床应用。
